var data={"title":"Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Central nervous system infections due to dematiaceous fungi (cerebral phaeohyphomycosis)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/contributors\" class=\"contributor contributor_credentials\">Gary M Cox, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/contributors\" class=\"contributor contributor_credentials\">Carol A Kauffman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/contributors\" class=\"contributor contributor_credentials\">Anna R Thorner, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;May 11, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dematiaceous fungi have melanin-like pigments in the cell walls and can cause a variety of infections in humans known as phaeohyphomycosis (phaeo is Greek for &quot;dark&quot;). The most severe of the phaeohyphomycoses are infections of the central nervous system. The nomenclature of these infections is confusing, and there are scant data on appropriate management. The mycology, clinical features, and treatment of cerebral phaeohyphomycosis will be reviewed here.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">MYCOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The common factor among the dematiaceous fungi is the presence of melanin pigments in the cell walls and spores. These pigments cause the hyphae to appear golden brown when examined under the microscope, and this can sometimes suggest the diagnosis when examining clinical histopathology specimens. The fungal nomenclature of the agents of cerebral phaeohyphomycosis has undergone much change, and this has resulted in confusion about the identities of the causative fungi. The most common causes of cerebral phaeohyphomycosis, for example, are <em>Cladosporium trichoides</em> [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/1,2\" class=\"abstract_t\">1,2</a>], <em>Xylohypha bantiana</em> [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/3-7\" class=\"abstract_t\">3-7</a>], <em>Cladosporium bantianum</em> [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/8\" class=\"abstract_t\">8</a>], and <em>Cladophialophora bantiana</em> [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/9\" class=\"abstract_t\">9</a>]. It is now generally accepted that all of these fungi should be collectively known as <em>Cladophialophora bantiana</em>. One can assume that all of the previous reports on infections due to these seemingly different fungi were caused by the same species.</p><p>Other causative fungi include <em>Wangiella dermatitidis</em> (also known as <em>Exophiala dermatitidis</em>) [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/10,11\" class=\"abstract_t\">10,11</a>], <em>Dactylaria gallopava</em> (also known as <em>Ochroconis gallopava</em>) [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/12,13\" class=\"abstract_t\">12,13</a>], <em>Fonsecaea pedrosoi</em> [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/14\" class=\"abstract_t\">14</a>], <em>Bipolaris spicifera</em> (also known as <em>Drechslera spicifera</em>) [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/15,16\" class=\"abstract_t\">15,16</a>], <em>Rhinocladiella mackenziei</em> (also known as <em>Ramichloridium mackenziei</em> and <em>Ramichloridium obovoideum</em>) [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/17,18\" class=\"abstract_t\">17,18</a>], and <em>Aureobasidium species</em> [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/19\" class=\"abstract_t\">19</a>]. Specimens are frequently not cultured; thus, species identifications are often not made [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/20\" class=\"abstract_t\">20</a>]. In these cases, the diagnosis of phaeohyphomycosis depends upon demonstration of pigmented fungal structures by histopathology.</p><p>The dematiaceous fungi are found throughout the world in soil and decaying vegetation but appear to be especially common in tropical and subtropical regions. Most patients infected with <em>R. mackenziei</em> have been from Middle Eastern countries, including Saudi Arabia, Syria, or Kuwait [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/17,18,21,22\" class=\"abstract_t\">17,18,21,22</a>], but cases have also been reported from India [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/23\" class=\"abstract_t\">23</a>], Afghanistan [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/24\" class=\"abstract_t\">24</a>], and Pakistan [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/25\" class=\"abstract_t\">25</a>].</p><p><em>D. gallopava</em> can causes encephalitis in turkeys, chickens, and other birds, but exposure to birds has not been linked to human disease [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/26-28\" class=\"abstract_t\">26-28</a>].</p><p class=\"headingAnchor\" id=\"H1148989244\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cerebral infections are thought to be due to extension from the adjacent paranasal sinuses. It is presumed that spores enter the sinuses after inhalation and then proliferate, especially when the sinuses are obstructed. Some infections appear to have resulted directly from penetrating trauma to the head or from contaminated wounds [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/15\" class=\"abstract_t\">15</a>]. Hematogenous dissemination to the CNS has been postulated in some case reports, including a patient with localized skin lesions [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/19\" class=\"abstract_t\">19</a>], an injection drug user [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/9\" class=\"abstract_t\">9</a>], and a heart-lung transplant patient with pneumonitis [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/29\" class=\"abstract_t\">29</a>].</p><p class=\"headingAnchor\" id=\"H1148989296\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately one-half of the patients described in a review of 101 cases of central nervous system (CNS) phaeohyphomycosis had no apparent immunocompromising condition [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/21\" class=\"abstract_t\">21</a>]. Among immunocompromised patients, most cases have occurred in solid organ transplant recipients [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/1,12,21,29\" class=\"abstract_t\">1,12,21,29</a>], patients with malignancies [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/13\" class=\"abstract_t\">13</a>], and HIV-infected patients who injected illicit drugs [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/30\" class=\"abstract_t\">30</a>].</p><p class=\"headingAnchor\" id=\"H68249220\"><span class=\"h2\">Outbreak of fungal meningitis and septic arthritis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A multistate outbreak of fungal CNS infection and septic arthritis was detected in the United States in late September 2012, when patients who had received epidural injections of <a href=\"topic.htm?path=methylprednisolone-drug-information\" class=\"drug drug_general\">methylprednisolone</a> produced at a single compounding center (New England Compounding Center) developed meningitis with or without posterior circulation stroke and patients who received intraarticular injections of the same drug developed septic arthritis [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/31,32\" class=\"abstract_t\">31,32</a>]. During the early investigation, the most common pathogen isolated from patients affected by the outbreak was <em>Exserohilum</em> spp (<a href=\"image.htm?imageKey=ID%2F86772\" class=\"graphic graphic_picture graphicRef86772 \">picture 1</a>), a dematiaceous (brown-black) fungus, but other pathogens were also detected (eg, <em>Aspergillus fumigatus</em>, <em>Cladosporium</em> spp) [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/32,33\" class=\"abstract_t\">32,33</a>]. The outbreak is discussed in detail separately. (See <a href=\"topic.htm?path=outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Most cases of cerebral phaeohyphomycosis present as a brain abscess with focal neurologic deficits <span class=\"nowrap\">and/or</span> generalized seizures. Fever and headache are uncommon. Symptomatic sinusitis or localized infection due to dematiaceous fungi at another site is very rare. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-brain-abscess\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of brain abscess&quot;</a>.)</p><p>Neuroimaging studies usually show a single enhancing hypodense lesion in the frontal or parietal lobe, although many patients, especially those with underlying immunocompromising conditions, present with multiple lesions [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/34\" class=\"abstract_t\">34</a>]. Meningeal enhancement is unusual, and there have been no reports of adjacent bone involvement.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis can be made by aspiration of the abscess or by surgical resection. Microscopic examination of the fluid may reveal branching, septate hyphae that usually appear brown on hematoxylin and eosin staining or on KOH preparations of the material. However, the hyphae sometimes do not have pigment; in these instances, special stains for melanin can be used, such as the Fontana-Masson stain. Silver stains will obscure the fungi so that the brown color cannot be seen. Fungi in this group grow relatively quickly from clinical specimens. Identification of the species is based mostly upon morphology of sporulating cultures and often requires the assistance of reference laboratories.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The treatment of cerebral phaeohyphomycosis requires both resection of the abscess and antifungal therapy. Complete surgical evacuation is optimal and is associated with a higher rate of success when compared with computed tomographic&ndash;guided aspiration. However, surgical removal of the abscess alone without antifungal therapy will most likely result in failure [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/35\" class=\"abstract_t\">35</a>]. Susceptibility testing of the dematiaceous fungi has not been standardized; various studies have shown that many of these organisms are susceptible to <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a>, <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a>, <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a>, <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>, echinocandins, <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a>, or amphotericin B [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/36-42\" class=\"abstract_t\">36-42</a>]. (See <a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;</a> and <a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">&quot;Pharmacology of amphotericin B&quot;</a>.)</p><p>Reasonable recommendations for therapy, based upon the outcomes of published cases, should include surgical resection of the abscess and the administration of both amphotericin B and an azole (<a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> with a loading dose of 6 <span class=\"nowrap\">mg/kg</span> intravenously [IV] every 12 hours for two doses, then 4 <span class=\"nowrap\">mg/kg</span> IV twice daily, or <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> [200 mg orally twice daily], or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> delayed-release tablets [300 mg every 12 hours on the first day, then 300 mg once daily] [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/43\" class=\"abstract_t\">43</a>]). We prefer <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> (AmBisome, 3 to 5 <span class=\"nowrap\">mg/kg</span> IV once daily) to <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (0.7 <span class=\"nowrap\">mg/kg</span> IV once daily) given that the former agent is associated with less nephrotoxicity and infusion-related reactions and has improved central nervous system (CNS) penetration in animal models. Among the azoles listed above, we prefer voriconazole because it has the best CNS penetration and is available as an intravenous formulation, which allows clinicians to rapidly and more reliably achieve therapeutic drug levels when initiating therapy.</p><p><a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">Voriconazole</a> can be switched to the oral formulation at 200 mg twice daily if the patient is stable and is expected to be able to absorb oral medications. Amphotericin B can be stopped and therapy with the azole alone continued once the patient has had a clinical response and there has been documentation of therapeutic serum levels of the azole. (See <a href=\"topic.htm?path=pharmacology-of-azoles#H26\" class=\"medical medical_review\">&quot;Pharmacology of azoles&quot;, section on 'Serum drug concentration monitoring'</a>.)</p><p>Antifungal therapy should continue for at least six months, and courses of up to two years have been used. Survival rates for cerebral phaeohyphomycosis have improved with the availability of <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> and <a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> and are approximately 50 percent at two years [<a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/21,44\" class=\"abstract_t\">21,44</a>].</p><p>The experience with using <a href=\"topic.htm?path=terbinafine-drug-information\" class=\"drug drug_general\">terbinafine</a>, <a href=\"topic.htm?path=flucytosine-drug-information\" class=\"drug drug_general\">flucytosine</a>, and echinocandins for cerebral infections is based on a few individual case reports, and it is not possible to recommend the use of these agents.</p><p class=\"headingAnchor\" id=\"H1148989144\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Dematiaceous fungi have melanin-like pigments in the cell walls and can cause a variety of infections in humans known as phaeohyphomycosis (phaeo is Greek for &quot;dark&quot;). The most severe of the phaeohyphomycoses are infections of the central nervous system (CNS). (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The fungal nomenclature of the agents of cerebral phaeohyphomycosis has undergone much change, and this has resulted in confusion about the identities of the causative fungi. The most common causes of cerebral phaeohyphomycosis, for example, are <em>Cladophialophora bantiana</em>, <em>Wangiella dermatitidis</em>, and <em>Rhinocladiella mackenziei</em>. (See <a href=\"#H2\" class=\"local\">'Mycology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The dematiaceous fungi are found throughout the world in soil and decaying vegetation but appear to be especially common in tropical and subtropical regions. Most patients infected with <em>R. mackenziei</em> have been from the Middle East and Southeast Asia. (See <a href=\"#H2\" class=\"local\">'Mycology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most cerebral infections are thought to be due to extension from the adjacent paranasal sinuses. It is presumed that spores enter the sinuses after inhalation and then proliferate, especially when the sinuses are obstructed. (See <a href=\"#H1148989244\" class=\"local\">'Pathogenesis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Approximately one-half of the patients with CNS phaeohyphomycosis have no apparent immunocompromising condition. Among immunocompromised patients, most cases have occurred in solid organ transplant recipients, patients with malignancies, and HIV-infected patients who injected illicit drugs. (See <a href=\"#H1148989296\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most cases of cerebral phaeohyphomycosis present as a brain abscess with focal neurologic deficits <span class=\"nowrap\">and/or</span> generalized seizures. Fever and headache are uncommon. (See <a href=\"#H4\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis can be made by aspiration of the abscess or by surgical resection. Microscopic examination of the fluid may reveal branching, septate hyphae that usually appear brown on hematoxylin and eosin staining or on KOH preparations of the material. Identification of the species is based mostly upon morphology of sporulating cultures and often requires the assistance of reference laboratories. (See <a href=\"#H5\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The treatment of cerebral phaeohyphomycosis requires both resection of the abscess and antifungal therapy. Complete surgical evacuation is optimal and is associated with a higher rate of success when compared with computed tomographic&ndash;guided aspiration. (See <a href=\"#H6\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reasonable recommendations for therapy based upon the outcomes of published cases starts with surgical resection of the abscess and the administration of both amphotericin B and an azole (<a href=\"topic.htm?path=voriconazole-drug-information\" class=\"drug drug_general\">voriconazole</a> with a loading dose of 6 <span class=\"nowrap\">mg/kg</span> intravenously [IV] every 12 hours for two doses, then 4 <span class=\"nowrap\">mg/kg</span> IV twice daily, or <a href=\"topic.htm?path=itraconazole-drug-information\" class=\"drug drug_general\">itraconazole</a> [200 mg orally twice daily], or <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> delayed-release tablets [300 mg every 12 hours on the first day, then 300 mg once daily]). We prefer <a href=\"topic.htm?path=liposomal-amphotericin-b-drug-information\" class=\"drug drug_general\">liposomal amphotericin B</a> (AmBisome, 3 to 5 <span class=\"nowrap\">mg/kg</span> IV once daily) to <a href=\"topic.htm?path=amphotericin-b-deoxycholate-conventional-drug-information\" class=\"drug drug_general\">amphotericin B deoxycholate</a> (0.7 <span class=\"nowrap\">mg/kg</span> IV once daily) given that the former agent is associated with less nephrotoxicity and infusion-related reactions and has improved CNS penetration in animal models. Among the azoles listed above, we prefer voriconazole because it has the best CNS penetration and is available in an intravenous formulation. (See <a href=\"#H6\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antifungal therapy should continue for at least six months, and courses of up to two years have been used. (See <a href=\"#H6\" class=\"local\">'Treatment'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/1\" class=\"nounderline abstract_t\">Aldape KD, Fox HS, Roberts JP, et al. Cladosporium trichoides cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case. Am J Clin Pathol 1991; 95:499.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/2\" class=\"nounderline abstract_t\">Banerjee U, Mohapatra AK, Sarkar C, Chaudhery R. Cladosporiosis (cerebral phaeohyphomycosis) of brain--a case report. Mycopathologia 1989; 105:163.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/3\" class=\"nounderline abstract_t\">Buxi TB, Prakash K, Vohra R, Bhatia D. Imaging in phaeohyphomycosis of the brain: case report. Neuroradiology 1996; 38:139.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/4\" class=\"nounderline abstract_t\">Lirng JF, Tien RD, Osumi AK, et al. Cerebral phaeohyphomycosis complicated with brain abscess: a case report. Zhonghua Yi Xue Za Zhi (Taipei) 1995; 55:491.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/5\" class=\"nounderline abstract_t\">Mukherji SK, Castillo M. Cerebral phaeohyphomycosis caused by Xylohypha bantiana: MR findings. AJR Am J Roentgenol 1995; 164:1304.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/6\" class=\"nounderline abstract_t\">Palaoglu S, Sav A, Basak T, et al. Cerebral phaeohyphomycosis. Neurosurgery 1993; 33:894.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/7\" class=\"nounderline abstract_t\">Sekhon AS, Galbraith J, Mielke BW, et al. Cerebral phaeohyphomycosis caused by Xylohypha bantiana, with a review of the literature. Eur J Epidemiol 1992; 8:387.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/8\" class=\"nounderline abstract_t\">Hironaga M, Watanabe S. Cerebral phaeohyphomycosis caused by Cladosporium bantianum: a case in a female who had cutaneous alternariosis in her childhood. Sabouraudia 1980; 18:229.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/9\" class=\"nounderline abstract_t\">Walz R, Bianchin M, Chaves ML, et al. Cerebral phaeohyphomycosis caused by Cladophialophora bantiana in a Brazilian drug abuser. J Med Vet Mycol 1997; 35:427.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/10\" class=\"nounderline abstract_t\">Chang CL, Kim DS, Park DJ, et al. Acute cerebral phaeohyphomycosis due to Wangiella dermatitidis accompanied by cerebrospinal fluid eosinophilia. J Clin Microbiol 2000; 38:1965.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/11\" class=\"nounderline abstract_t\">Tintelnot K, de Hoog GS, Thomas E, et al. Cerebral phaeohyphomycosis caused by an Exophiala species. Mycoses 1991; 34:239.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/12\" class=\"nounderline abstract_t\">Vukmir RB, Kusne S, Linden P, et al. Successful therapy for cerebral phaeohyphomycosis due to Dactylaria gallopava in a liver transplant recipient. Clin Infect Dis 1994; 19:714.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/13\" class=\"nounderline abstract_t\">Sides EH 3rd, Benson JD, Padhye AA. Phaeohyphomycotic brain abscess due to Ochroconis gallopavum in a patient with malignant lymphoma of a large cell type. J Med Vet Mycol 1991; 29:317.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/14\" class=\"nounderline abstract_t\">al-Hedaithy SS, Jamjoom ZA, Saeed ES. Cerebral phaeohyphomycosis caused by Fonsecaea pedrosoi in Saudi Arabia. APMIS Suppl 1988; 3:94.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/15\" class=\"nounderline abstract_t\">Biggs PJ, Allen RL, Powers JM, Holley HP Jr. Phaeohyphomycosis complicating compound skull fracture. Surg Neurol 1986; 25:393.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/16\" class=\"nounderline abstract_t\">Yoshimori RN, Moore RA, Itabashi HH, Fujikawa DG. Phaeohyphomycosis of brain: granulomatous encephalitis caused by Drechslera spicifera. Am J Clin Pathol 1982; 77:363.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/17\" class=\"nounderline abstract_t\">Podnos YD, Anastasio P, De La Maza L, Kim RB. Cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (Ramichloridium mackenziei): case report. Neurosurgery 1999; 45:372.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/18\" class=\"nounderline abstract_t\">Sutton DA, Slifkin M, Yakulis R, Rinaldi MG. U.S. case report of cerebral phaeohyphomycosis caused by Ramichloridium obovoideum (R. mackenziei): criteria for identification, therapy, and review of other known dematiaceous neurotropic taxa. J Clin Microbiol 1998; 36:708.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/19\" class=\"nounderline abstract_t\">Fletcher H, Williams NP, Nicholson A, et al. Systemic phaeohyphomycosis in pregnancy and the puerperium. West Indian Med J 2000; 49:79.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/20\" class=\"nounderline abstract_t\">Masini T, Riviera L, Cappricci E, Arienta C. Cerebral phaeohyphomycosis. Clin Neuropathol 1985; 4:246.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/21\" class=\"nounderline abstract_t\">Revankar SG, Sutton DA, Rinaldi MG. Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis 2004; 38:206.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/22\" class=\"nounderline abstract_t\">Kantarcioglu AS, de Hoog GS. Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004. Mycoses 2004; 47:4.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/23\" class=\"nounderline abstract_t\">Badali H, Chander J, Bansal S, et al. First autochthonous case of Rhinocladiella mackenziei cerebral abscess outside the Middle East. J Clin Microbiol 2010; 48:646.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/24\" class=\"nounderline abstract_t\">Cristini A, Garcia-Hermoso D, Celard M, et al. Cerebral phaeohyphomycosis caused by Rhinocladiella mackenziei in a woman native to Afghanistan. J Clin Microbiol 2010; 48:3451.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/25\" class=\"nounderline abstract_t\">Jabeen K, Farooqi J, Zafar A, et al. Rhinocladiella mackenziei as an emerging cause of cerebral phaeohyphomycosis in Pakistan: a case series. Clin Infect Dis 2011; 52:213.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/26\" class=\"nounderline abstract_t\">Salkin IF, Dixon DM, Kemna ME, et al. Fatal encephalitis caused by Dactylaria constricta var. gallopava in a snowy owl chick (Nyctea scandiaca). J Clin Microbiol 1990; 28:2845.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/27\" class=\"nounderline abstract_t\">Blalock HG, Georg LK, Derieux WT. Encephalitis in turkey poults due to Dactylaria (Diplorhinotrichum) gallopava--a case report and its experimental reproduction. Avian Dis 1973; 17:197.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/28\" class=\"nounderline abstract_t\">Ranck FM Jr, Georg LK, Wallace DH. Dactylariosis--a newly recognized fungus disease of chickens. Avian Dis 1974; 18:4.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/29\" class=\"nounderline abstract_t\">Levin TP, Baty DE, Fekete T, et al. Cladophialophora bantiana brain abscess in a solid-organ transplant recipient: case report and review of the literature. J Clin Microbiol 2004; 42:4374.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/30\" class=\"nounderline abstract_t\">del Palacio-Hernanz A, Moore MK, Campbell CK, et al. Infection of the central nervous system by Rhinocladiella atrovirens in a patient with acquired immunodeficiency syndrome. J Med Vet Mycol 1989; 27:127.</a></li><li class=\"breakAll\">Centers for Disease Control and Prevention. Multi-state meningitis outbreak. http://www.cdc.gov/hai/outbreaks/meningitis.html (Accessed on January 15, 2013).</li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/32\" class=\"nounderline abstract_t\">Centers for Disease Control and Prevention (CDC). Multistate outbreak of fungal infection associated with injection of methylprednisolone acetate solution from a single compounding pharmacy - United States, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:839.</a></li><li class=\"breakAll\">Center for Infectious Disease Research &amp; Policy. Warnings, cases expand in fungal meningitis outbreak. http://www.cidrap.umn.edu/cidrap/content/other/news/oct1612fungusbr.html (Accessed on October 17, 2012).</li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/34\" class=\"nounderline abstract_t\">Roche M, Redmond RM, O'Neill S, Smyth E. A case of multiple cerebral abscesses due to infection with Cladophialophora bantiana. J Infect 2005; 51:e285.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/35\" class=\"nounderline abstract_t\">Delfino D, De Hoog S, Polonelli L, et al. Survival of a neglected case of brain abscess caused by Cladophialophora bantiana. Med Mycol 2006; 44:651.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/36\" class=\"nounderline abstract_t\">Al-Abdely HM, Najvar L, Bocanegra R, et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (&quot;Ramichloridium mackenziei&quot;). Antimicrob Agents Chemother 2000; 44:1159.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/37\" class=\"nounderline abstract_t\">Caligiorne RB, Resende MA, Melillo PH, et al. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol 1999; 37:405.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/38\" class=\"nounderline abstract_t\">Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001; 150:101.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/39\" class=\"nounderline abstract_t\">Fothergill AW, Rinaldi MG, Sutton DA. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole. Med Mycol 2009; 47:41.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/40\" class=\"nounderline abstract_t\">Rivard RG, McCall S, Griffith ME, et al. Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection. Med Mycol 2007; 45:685.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/41\" class=\"nounderline abstract_t\">Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20:121.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/42\" class=\"nounderline abstract_t\">Deng S, Pan W, Liao W, et al. Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis. Antimicrob Agents Chemother 2016; 60:2346.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/43\" class=\"nounderline abstract_t\">Proia LA, Trenholme GM. Chronic refractory phaeohyphomycosis: successful treatment with posaconazole. Mycoses 2006; 49:519.</a></li><li><a href=\"https://www.uptodate.com/contents/central-nervous-system-infections-due-to-dematiaceous-fungi-cerebral-phaeohyphomycosis/abstract/44\" class=\"nounderline abstract_t\">Matsumoto T, Matsuda T, McGinnis MR, Ajello L. Clinical and mycological spectra of Wangiella dermatitidis infections. Mycoses 1993; 36:145.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 2417 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1148989144\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">MYCOLOGY</a></li><li><a href=\"#H1148989244\" id=\"outline-link-H1148989244\">PATHOGENESIS</a></li><li><a href=\"#H1148989296\" id=\"outline-link-H1148989296\">EPIDEMIOLOGY</a><ul><li><a href=\"#H68249220\" id=\"outline-link-H68249220\">Outbreak of fungal meningitis and septic arthritis</a></li></ul></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL FEATURES</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">DIAGNOSIS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">TREATMENT</a></li><li><a href=\"#H1148989144\" id=\"outline-link-H1148989144\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/2417|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/86772\" class=\"graphic graphic_picture\">- Exserohilum rostratum</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=outbreak-of-fungal-central-nervous-system-and-osteoarticular-infections-in-the-united-states-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Outbreak of fungal central nervous system and osteoarticular infections in the United States: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-brain-abscess\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of brain abscess</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-amphotericin-b\" class=\"medical medical_review\">Pharmacology of amphotericin B</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pharmacology-of-azoles\" class=\"medical medical_review\">Pharmacology of azoles</a></li></ul></div></div>","javascript":null}